The Drug Development Letter
Vinay Prasad, Timothée Olivier, John-John Schnog, Sahar van Waalwijk, Ashley DuitsWe cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases
| Platform |  | Pricing | Freemium | Publishes | Daily |
|---|---|---|---|---|---|
| Issues | 83 | Subscribers | Read | drugdevletter.com |
Curious about how many subscribers The Drug Development Letter has or want to find similar newsletters? Reletter has got you covered. We collated all the information we could find from across the web in our database of over one million newsletters.
Check the email archives, get traffic estimates, engagement scores and more to discover the best advertising opportunities.
Our search tool helps you locate relevant newsletters for any topic and compare their stats for better sponsorship decisions.
Chart Rankings
How this newsletter ranks in the official Substack charts.
| #247 | |
| #164 |
Latest Issues
Recent posts by this newsletter. Browse the email archive.
Can quality of life research learn from restaurant reviews?
Imagine you’re trying to book a restaurant and checking reviews, but each restaurant is rated on a different platform, with varying criteria and scoring systems. Some platforms send out their questionnaires only in the summer, favouring res...
How to design a trial to test the efficacy of Lutetium-PSMA products in metastatic castration-resistant prostate cancer?
Following a recent post on the SPLASH trial, which outlined various issues with its design, I received the following question.
SPLASH - a problematic trial design for an active Lutetium-PSMA product in metastatic castrate-resistant prostate cancer
During the European Society for Medical Oncology (ESMO) annual meeting in 2024, results from the SPLASH trial were presented. SPLASH is evaluating a Lutetium-PSMA product in patients with PSMA-positive, metastatic castration-resistant prost...
After 23 years, imatinib remains the best front-line therapy in CML. Why use accelerated approval in a setting where patients have a life expectancy comparable to the general population?
Here is a thread I posted on X after asciminib was approved by the US FDA under the accelerated pathway.
Authors
The writers behind this newsletter.
Hematology Oncology Medicine Health Policy Epidemiology Professor
Medical oncologist based in Geneva University Hospital (Switzerland), I joined Vinay Prasad's research lab (@vkprasadlab) at University of California San Francisco (UCSF) in November 2021.
Internist-hematologist/medical oncologist Curaçao
Pharmacist Medicine & Society (PharmD-PhD), National Funder’s Committee for Evaluation of Specialised Medicines and Companion Diagnostics, CZ. Associate Professor of Medical Oncology and Accessibility of Medicine, LUMC, NL
Medical Immunologist with great interest for achieving true value healthcare including social justice and DEI. Medical education of young doctors is essential for achieving the necessary changes in healthcare.
Frequently Asked Questions
How can I access the email archive for The Drug Development Letter?
You can find recent issues that have been published by The Drug Development Letter on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does The Drug Development Letter have?
To see how many people subscribe to The Drug Development Letter, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in The Drug Development Letter?
Newsletter advertising can be extremely effective when it's done right. Before you pitch The Drug Development Letter as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like The Drug Development Letter?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact The Drug Development Letter using the contact information provided and ask for a copy of their media kit.
How can I find newsletters similar to The Drug Development Letter?
Scroll up to where it says Similar Newsletters to see other publications like The Drug Development Letter. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact The Drug Development Letter?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.